[HTML][HTML] Anaplastic lymphoma kinase inhibitor development: enhanced delivery to the central nervous system
T Hida - Translational Lung Cancer Research, 2023 - ncbi.nlm.nih.gov
Ceritinib is a second-generation ALK TKI, and in a murine experiment, the blood-to-brain
transition ratio of ceritinib reached 15%(11). In the phase I trial (ASCEND-1), ceritinib …
transition ratio of ceritinib reached 15%(11). In the phase I trial (ASCEND-1), ceritinib …
[引用][C] Anaplastic lymphoma kinase inhibitor development: enhanced delivery to the central nervous system
T Hida - Translational lung cancer research, 2023 - pubmed.ncbi.nlm.nih.gov
Anaplastic lymphoma kinase inhibitor development: enhanced delivery to the central nervous system
T Hida - europepmc.org
Ceritinib is a second-generation ALK TKI, and in a murine experiment, the blood-to-brain
transition ratio of ceritinib reached 15%(11). In the phase I trial (ASCEND-1), ceritinib …
transition ratio of ceritinib reached 15%(11). In the phase I trial (ASCEND-1), ceritinib …
[PDF][PDF] Anaplastic lymphoma kinase inhibitor development: enhanced delivery to the central nervous system
T Hida - cdn.amegroups.cn
Ceritinib is a second-generation ALK TKI, and in a murine experiment, the blood-to-brain
transition ratio of ceritinib reached 15%(11). In the phase I trial (ASCEND-1), ceritinib …
transition ratio of ceritinib reached 15%(11). In the phase I trial (ASCEND-1), ceritinib …
[HTML][HTML] Anaplastic lymphoma kinase inhibitor development: enhanced delivery to the central nervous system
T Hida - Translational Lung Cancer Research, 2023 - tlcr.amegroups.org
Anaplastic lymphoma kinase (ALK) gene rearrangement is a potent oncogenic driver in non-
small cell lung cancer (NSCLC) and occurs in about 5% of patients with NSCLC (1). ALK …
small cell lung cancer (NSCLC) and occurs in about 5% of patients with NSCLC (1). ALK …
[引用][C] Anaplastic lymphoma kinase inhibitor development: enhanced delivery to the central nervous system
T Hida - Translational Lung Cancer Research, 2023 - tlcr.amegroups.org
Anaplastic lymphoma kinase inhibitor development: enhanced delivery to the central
nervous system - Hida - Translational Lung Cancer Research Have a website account?Log …
nervous system - Hida - Translational Lung Cancer Research Have a website account?Log …
[引用][C] Anaplastic lymphoma kinase inhibitor development: enhanced delivery to the central nervous system.
T Hida - Translational Lung Cancer Research, 2023 - europepmc.org
Anaplastic lymphoma kinase inhibitor development: enhanced delivery to the central nervous
system. - Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu …
system. - Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu …